Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies

被引:0
|
作者
Kaiyue Wang
Lu Shen
Wei Tian
Suzhan Zhang
机构
[1] Zhejiang University,Department of Breast Surgery, the Second Affiliated Hospital, School of Medicine
[2] Zhejiang University,Cancer Institute (The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), Department of Surgical Oncology, the Second Affiliated Hospital, School of Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Adjuvant endocrine therapy improves the prognosis of early breast cancer with hormone receptor positivity. However, there is no systematic report on the effect of endocrine therapy (particularly ovarian function suppression, OFS) on serum lipids in premenopausal women. This retrospective cohort study aimed to determine whether various endocrine treatments had different effects on blood lipids. This study enrolled 160 premenopausal patients with stage I–III breast cancer in eastern China. The initial diagnostic information was retrieved from patient's medical records, including age at the time of diagnosis, tumor characteristics, anticancer treatment and past medical history. The changes in blood lipids in patients receiving different types of endocrine therapy were compared at the 3rd, 6th, 12th, and 24th months after initiating endocrine therapy. Generalized linear mixed model was used in our analyses. Our data revealed that low-density lipoprotein cholesterol (LDL-C) levels in patients with tamoxifen (TAM) were significantly lower in the 6th, 12th, and 24th months than that in the 3rd month, while high-density lipoprotein cholesterol (HDL-C) levels in the 6th, 12th, and 24th months were significantly higher than that in the 3rd month, indicating that blood lipid levels generally improved with time. While in TAM plus OFS group, HDL-C levels were significantly higher in the 24th month than in the 3rd month, total cholesterol (TC) levels were significantly higher in the 24th month than in the 6th month. The lipid profiles of OFS plus aromatase inhibitor (AI) group did not show significant differences at any time point but were significantly higher than those of the other two groups especially in LDL and TC. TAM group tended to have lower serum lipid levels. With longer follow-up, no statistically significant difference in values was observed between TAM and TAM plus OFS groups at various time points. Compared with the other two groups, OFS plus AI group presented an increasing trend toward LDL-C and TC. The risk of dyslipidemia requires further investigation using a large sample size.
引用
收藏
相关论文
共 50 条
  • [1] Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
    Wang, Kaiyue
    Shen, Lu
    Tian, Wei
    Zhang, Suzhan
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [2] Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study
    Tian, Wei
    Wu, Miaowei
    Deng, Yongchuan
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (08): : 837 - 843
  • [3] The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
    Kang, Yi-Kun
    Wang, Xue
    Hu, Nan-Lin
    Yue, Jian
    Si, Yi-Ran
    Ju, Jie
    Gao, Song-Lin
    Yuan, Peng
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Hormone Therapy in Premenopausal Women with Early-Stage Breast Cancer
    Rugo, Hope S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 175 - 176
  • [5] Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer
    Lambertini, Matteo
    Del Mastro, Lucia
    Viglietti, Giulia
    Ponde, Noam F.
    Solinas, Cinzia
    de Azambuja, Evandro
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)
  • [6] Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer
    Matteo Lambertini
    Lucia Del Mastro
    Giulia Viglietti
    Noam F. Pondé
    Cinzia Solinas
    Evandro de Azambuja
    [J]. Current Treatment Options in Oncology, 2017, 18
  • [7] Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
    Venturelli, Marta
    Guaitoli, Giorgia
    Omarini, Claudia
    Moscetti, Luca
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2018, 10 : 39 - 49
  • [8] Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole
    Bell, Lauren Nicole
    Anne Thi Phuong Nguyen
    Li, Lang
    Desta, Zeruesenay
    Henry, N. Lynn
    Hayes, Daniel F.
    Wolff, Antonio C.
    Stearns, Vered
    Storniolo, Anna Maria
    Flockhart, David A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (12): : 1852 - 1860
  • [9] Cognitive sequelae of adjuvant endocrine therapy in older women treated for early-stage breast cancer
    Underwood, Emily A.
    Pritchard, Kathleen I.
    Jerzak, Katarzyna
    Lebovic, Gerald
    Elser, Christine
    Rochon, Paula
    Tierney, Mary C.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [10] Changes in lipid profiles during and after (neo) adjuvant chemotherapy in women with early-stage breast cancer: A retrospective study
    Tian, Wei
    Yao, Yihan
    Fan, Guocai
    Zhou, Yunxiang
    Wu, Miaowei
    Xu, Dong
    Deng, Yongchuan
    [J]. PLOS ONE, 2019, 14 (08):